Literature DB >> 29145955

Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2.

Hui-Ming Chang1, Tochukwu M Okwuosa2, Tiziano Scarabelli3, Rohit Moudgil4, Edward T H Yeh5.   

Abstract

In this second part of a 2-part review, we will review cancer or cancer therapy-associated systemic and pulmonary hypertension, QT prolongation, arrhythmias, pericardial disease, and radiation-induced cardiotoxicity. This review is based on a MEDLINE search of published data, published clinical guidelines, and best practices in major cancer centers. Newly developed targeted therapy can exert off-target effects causing hypertension, thromboembolism, QT prolongation, and atrial fibrillation. Radiation therapy often accelerates atherosclerosis. Furthermore, radiation can damage the heart valves, the conduction system, and pericardium, which may take years to manifest clinically. Management of pericardial disease in cancer patients also posed clinical challenges. This review highlights the unique opportunity of caring for cancer patients with heart problems caused by cancer or cancer therapy. It is an invitation to action for cardiologists to become familiar with this emerging subspecialty.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer therapy; cardiovascular complication; hypertension; radiation therapy; thromboembolism

Mesh:

Year:  2017        PMID: 29145955      PMCID: PMC5825188          DOI: 10.1016/j.jacc.2017.09.1095

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  146 in total

1.  Post-radiation valvular and coronary artery disease.

Authors:  A T Gonzaga; M J Antunes
Journal:  J Heart Valve Dis       Date:  1997-03

2.  Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension.

Authors:  Murat Dincer; Kadri Altundag
Journal:  Ann Pharmacother       Date:  2006-11-14       Impact factor: 3.154

Review 3.  The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

Authors:  Darryl P Leong; François Caron; Christopher Hillis; Annie Duan; Jeff S Healey; Graeme Fraser; Deborah Siegal
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

4.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  Mechanisms of hypertension associated with BAY 43-9006.

Authors:  Maria Luisa Veronese; Ari Mosenkis; Keith T Flaherty; Maryann Gallagher; James P Stevenson; Raymond R Townsend; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-01-30       Impact factor: 44.544

6.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

7.  Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer.

Authors:  Isabel J Boero; Anthony J Paravati; Daniel P Triplett; Lindsay Hwang; Rayna K Matsuno; Erin F Gillespie; Catheryn M Yashar; Vitali Moiseenko; John P Einck; Loren K Mell; Sahil A Parikh; James D Murphy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-17       Impact factor: 7.038

8.  Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Authors:  Giuseppe Procopio; Elena Verzoni; Arpine Gevorgyan; Maddalena Mancin; Sara Pusceddu; Laura Catena; Marco Platania; Valentina Guadalupi; Antonia Martinetti; Emilio Bajetta
Journal:  Oncology       Date:  2008-04-16       Impact factor: 2.935

9.  Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival.

Authors:  D Dequanter; Ph Lothaire; T Berghmans; J P Sculier
Journal:  Ann Surg Oncol       Date:  2008-07-22       Impact factor: 5.344

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983

View more
  73 in total

Review 1.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

2.  Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome.

Authors:  Valerio De Stefano
Journal:  Haematologica       Date:  2018-09       Impact factor: 9.941

3.  [Oncology in anesthesia and operative intensive care medicine].

Authors:  B Sinner
Journal:  Anaesthesist       Date:  2018-02       Impact factor: 1.041

4.  Cancer and the heart.

Authors:  Rebecca Dobson; David J Wright
Journal:  Br J Gen Pract       Date:  2018-05       Impact factor: 5.386

Review 5.  The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?

Authors:  Serban Mihai Balanescu; Dinu Valentin Balanescu; Teodora Donisan; Eric H Yang; Nicolas Palaskas; Juan Lopez-Mattei; Saamir Hassan; Peter Kim; Mehmet Cilingiroglu; Konstantinos Marmagkiolis; Biswajit Kar; Cezar Iliescu
Journal:  Curr Cardiol Rep       Date:  2019-07-08       Impact factor: 2.931

Review 6.  Cardiotoxicity of Novel Targeted Chemotherapeutic Agents.

Authors:  Isaac B Rhea; Guilherme H Oliveira
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-06-19

7.  c-Kit deficiency impairs nitric oxide signaling in smooth muscle cells.

Authors:  Diana R Hernandez; Miguel G Rojas; Laisel Martinez; Boris L Rodriguez; Zachary M Zigmond; Roberto I Vazquez-Padron; Roberta M Lassance-Soares
Journal:  Biochem Biophys Res Commun       Date:  2019-08-12       Impact factor: 3.575

8.  A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.

Authors:  Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

Review 9.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 10.  Modern concepts in cardio-oncology.

Authors:  Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.